Log in
Enquire now
Generex Biotechnology

Generex Biotechnology

Generex is a biotechnology and pharmaceutical company that develops and commercializes drug delivery systems and technologies for metabolic and immunological diseases.

OverviewStructured DataIssuesContributors

Contents

generex.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biology
Biology
Immunology
Immunology
Vaccine
Vaccine
Diagnosis
Diagnosis
Healthcare
Healthcare
Technology
Technology
Biotechnology
Biotechnology
...
Location
Burlington, Ontario
Burlington, Ontario
Miramar, Florida
Miramar, Florida
B2X
B2B
B2B
CEO
Joseph Moscato
Joseph Moscato
Number of Employees (Ranges)
51 – 2000
Phone Number
Full Address
4145 North Service Road, Suite 200, Burlington, ON Canada, L7L 6A3
10102 USA Today Way, SUITE 200, Miramar, FL, 33025
CIK Number
1,059,7840
Place of Incorporation
Delaware
Delaware
0
DUNS Number
1169241860
IRS Number
820,490,2110
Founded Date
1983
Total Funding Amount (USD)
9,350,000
Latest Funding Round Date
August 10, 2012
Business Model
Commerce
Stock Symbol
GNBT
Glassdoor ID
11971
Latest Funding Type
Private equity
Private equity
NAICS Code
325,4120
CAGE Code
8JPQ30
Headquarters
British Columbia
British Columbia

Other attributes

Company Operating Status
Active
SIC Code
2,8340

Generex is a biotechnology and pharmaceutical company that develops and commercializes drug delivery systems and technologies for metabolic and immunological diseases. The company was founded in 1983 in Miramar Beach, Florida, United States.

The company also looks to make strategic business decisions that allows them to provide management services, organize a network of pharmacies, clinical laboratories, and medical companies.

COVID-19

Along with its subsidiary, NuGenerex Immune-Oncology, Generex Biotechnology Corporation have launched a development platform for the development of a COVID-19 vaccine.

The company is looking to launch their vaccine using a li-key vaccine platform. The company has also signed a contract with EpiVax to use their tools in order to predict epitopes that will be used to generate peptide vaccines against the coronavirus. The companies together have identified hotspots in the amino acid sequences of the COVID-19 virus. The company will send their amino acids to China for the testing of the peptides in blood samples.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

COMPANY

https://www.generex.com/company

Web

CoronaVirus Cure (Joseph Moscato & Dr. Eric Von Hofe of Generex Biotechnology Corporation) Ep. #040

https://www.youtube.com/watch?v=uiHRa5hDrnw&feature=emb_logo

Generex Biotechnology | Crunchbase

https://www.crunchbase.com/organization/generex-biotechnology#section-current-team

Web

Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media

https://finance.yahoo.com/news/generex-ii-key-technology-development-184029270.html

Web

March 11, 2020

Press Release: Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic - EpiVax, Inc. - Informatics and Immunology

https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic

Web

March 4, 2020

References

Find more companies like Generex Biotechnology

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.